No connection

Search Results

INBS vs JAGX

INBS
Intelligent Bio Solutions Inc.
BEARISH
Price
$2.46
Market Cap
$4.9M
Sector
Healthcare
AI Confidence
95%
JAGX
Jaguar Health, Inc.
BEARISH
Price
$0.37
Market Cap
$4.6M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
INBS
--
JAGX
--
Forward P/E
INBS
7.03
JAGX
-0.06
P/B Ratio
INBS
0.27
JAGX
-0.13
P/S Ratio
INBS
1.37
JAGX
0.4
EV/EBITDA
INBS
-0.5
JAGX
-1.12

Profitability

Gross Margin
INBS
46.21%
JAGX
67.21%
Operating Margin
INBS
-290.89%
JAGX
-631.9%
Profit Margin
INBS
0.0%
JAGX
0.0%
ROE
INBS
-150.2%
JAGX
--
ROA
INBS
-51.17%
JAGX
-61.46%

Growth

Revenue Growth
INBS
47.6%
JAGX
-7.8%
Earnings Growth
INBS
--
JAGX
--

Financial Health

Debt/Equity
INBS
0.18
JAGX
--
Current Ratio
INBS
2.38
JAGX
0.5
Quick Ratio
INBS
2.17
JAGX
0.07

Dividends

Dividend Yield
INBS
--
JAGX
--
Payout Ratio
INBS
0.0%
JAGX
0.0%

AI Verdict

INBS BEARISH

The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.

Strengths
Strong YoY revenue growth of 47.60%
Low Debt-to-Equity ratio (0.18)
Healthy liquidity with a Current Ratio of 2.38
Risks
Critical financial health (Piotroski F-Score 1/9)
Extreme operating losses (Operating Margin -290.89%)
Severe price depreciation (down 79.8% over 1 year)
JAGX BEARISH

JAGX exhibits extreme financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a Quick Ratio of 0.07, suggesting it cannot meet short-term obligations. Despite a positive gross margin, the operating margin is catastrophic at -631.90%, and the stock has collapsed by 92.8% over the last year. The combination of declining revenue and consistent earnings misses points toward a high risk of insolvency.

Strengths
Positive Gross Margin (67.21%)
Low Price-to-Sales ratio (0.40)
Recent reduction in the magnitude of quarterly losses
Risks
Severe liquidity risk (Quick Ratio 0.07)
Negative equity (Price/Book -0.13)
Catastrophic operating losses (-631.90% margin)

Compare Another Pair

INBS vs JAGX: Head-to-Head Comparison

This page compares Intelligent Bio Solutions Inc. (INBS) and Jaguar Health, Inc. (JAGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile